Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Renal Cell Carcinoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

story of the week
Published in Renal Cell Carcinoma

Journal Scan / Research · January 25, 2021

Low Intratumor Heterogeneity Correlates With Increased Response to PD-1 Blockade in RCC

Therapeutic advances in medical oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Therapeutic advances in medical oncology
Low Intratumor Heterogeneity Correlates With Increased Response to PD-1 Blockade in Renal Cell Carcinoma
Ther Adv Med Oncol 2020 Dec 18;[EPub Ahead of Print], X Ran, J Xiao, Y Zhang, H Teng, F Cheng, H Chen, K Zhang, Z Sun

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading